Correlations between patterns of activity and the response to treatment yield distinct signatures for different antidepressive treatments

Stefan Spulber[1], Frederik Elberling[1], Sandra Ceccatelli[1], Martin Gärde[2], Mikael Tiger[2#], Johan Lundberg[2#]

[1] - Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.

[2] - Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Karolinska University Hospital, Stockholm, Sweden.

[#] - these authors contributed equally.

Corresponding author:

Stefan Spulber, MD PhD

Karolinska Institutet, Department of Neuroscience

Biomedicum D8

Solnavägen 6

171 65 Solna, Sweden

stefan.spulber@ki.se

Highlights

- Different antidepressant treatments alter specific subsets of features of activity patterns.
- The magnitude of response to treatment correlate with changes in patterns of activity.
- Patterns of activity correlate with the response to specific antidepressive treatments.

Abstract

Alterations in circadian patterns of activity have been described in several psychiatric disorders, and in major depressive disorder (MDD) have been associated with symptom severity. The aim of this study was to investigate the correlations between activity patterns and the response to different antidepressive treatments. We used actigraphy recordings acquired in three independent clinical trials investigating the response to internet-delivered cognitive behavioral therapy (iCBT), escitalopram, or ketamine, where symptom severity was assessed on MADRS scale. Data processing procedure was designed to extract features describing individual circadian cycles, as well as the average circadian profile for each subject. The analysis of effects of antidepressive treatments on single features (independently from magnitude of response) showed alterations in treatment-specific subsets of features. Further analysis revealed distinct correlations between longitudinal changes in individual features and the response to iCBT, escitalopram, or ketamine. Linear regression ensembles modeling the response to treatment were trained on actigraphy recorded during the depressive episode, before intervention. The analysis of coefficients following Bayesian model averaging showed that better response to iCBT was associated with weaker circadian entrainment; better response to ketamine was associated with more robust circadian entrainment and higher fragmentation of activity patterns; while higher age and steeper propensity to sustain activity was associated with better response to either iCBT or ketamine. Our data suggest that the analysis of circadian patterns of activity can potentially be used for predicting the response to specific MDD treatments, however larger confirmatory studies are required.

Introduction

Major depressive disorder (MDD) is a highly prevalent mental disorder with heterogenous biological background, and there are many antidepressive interventions available (Khan et al., 2012). Cognitive behavioral therapy (CBT) is well-established antidepressive non-pharmacological intervention (Weitz et al., 2015). Internet-delivered CBT (iCBT) has been shown to be as effective as face-to-face and has the advantage of using standardized treatment modules to ensure homogenous intervention suitable for longitudinal studies (Carlbring et al., 2017). Antidepressant drugs act on specific neurotransmitter signaling pathways, including serotonin, dopamine, noradrenaline, and glutamate. Selective serotonin reuptake inhibitors (SSRI) are the most commonly prescribed antidepressants, and it typically takes several weeks for the antidepressive effects to stabilize (Machado-Vieira et al., 2010). The introduction of rapid acting antidepressants, such as ketamine in subanesthetic dose (Berman et al., 2000) lead to a paradigm shift in the treatment of depression (Krystal et al., 2019).

The prediction of response to treatment is relevant particularly for the wellbeing of the patient as well as for avoiding unnecessary consumption of healthcare services. Several attempts have been described in the literature, including the change in reaction to facial expression early after starting the treatment (Browning et al., 2019), based on the patterns of change in scores for individual items after 4 weeks of treatment (Athreya et al., 2021), or using combinations of genetic and non-genetic biomarkers (Taliaz et al., 2021). While carrying undeniable advantages towards personalizing the MDD treatment, they either rely on treatment to be initiated before evaluation or require collecting biological samples for genotyping. Recording of movement by means of wrist actigraphy provides a promising non-invasive technology for data collection, and accumulating evidence points to associations between specific alterations in activity and different psychiatric disorders (Chapman et al., 2017; Kang et al., 2024; Pan et al., 2014; Tazawa et al., 2019). For MDD, the most common alterations reported are lower total amount of activity and blunted circadian rhythms (Lyall et al., 2018; Morres et al., 2019a). Similar associations have been described between activity levels and severity of depressive symptoms (Helgadóttir et al., 2015; Morres et al., 2019b), and we have shown recently that the patterns of activity correlate with depression severity independent of actual levels of activity (Spulber et al., 2022). However, the potential correlations between activity patterns and the response to treatment have received less attention to date.

The aim of this study was to investigate the correlations between activity patterns and the response to different MDD treatment alternatives. To this end we designed a features

extraction procedure including both sequence- and circadian profile-based features. We first

explored the effects of different antidepressive treatments on circadian patterns of activity in

MDD subjects. Second, we explored the changes in patterns of activity in relation to the

magnitude of response to treatment. Lastly, we trained multivariate linear regression

ensembles to fit the response to treatment and analyzed the impact and implications of

individual features.

Materials and methods

Data collection

We pooled together actigraphy recordings from 3 independent studies: (1) a study on

serotonin transporter availability in patients given internet-based Cognitive Behavioral

Therapy (iCBT) for the treatment of a major depressive episode (Svensson et al., 2021)

(Ethical Permit No. 2014/452-31, 2015/1177-32, Swedish Ethical Review Authority; pre-

registration: AsPredicted.org #14118). Healthy controls (HC, N=17) and subjects suffering

from depression (N=17) were recruited by advertisements in local newspapers. Diagnosis of

depression was established after full psychiatric assessment by a psychiatrist or by a resident

physician supervised by a senior psychiatrist using the Mini International Neuropsychiatric

Interview (M.I.N.I.). The study included patients with an ongoing major depressive episode

according to DSM-IV criteria, with a history of at least one prior episode, and which were not

undergoing any psychopharmacological treatment for MDD. Eligible patients had a MADRS

score between 18 and 35. HC had no history of psychiatric illness and matched the patients by

age, sex, and intellectual ability. The iCBT protocol consisted of 10 modules delivered in an

online program. Throughout the program, the patients had been assigned to a psychologist

who supervises the progress and provides individual feedback (Svensson et al., 2021). The

study participants were instructed to wear the actigraph (GENEActiv, ActivInsights, Cambs,

UK) continuously on the wrist of the non-dominant arm. In MDD patients, actigraphy

recordings were acquired before starting, and after completing the iCBT program. (2) a study

on the effects of escitalopram treatment on serotonin 1B receptor binding in MDD (Gärde et

al., 2024) (Ethical Permit No. 2018/1403-31/1, Swedish Ethical Review Authority; pre-

registration: AsPredicted.org #33267). The patients were recruited via online advertising and

from Gustavsberg University Primary Care Center (Stockholm County, Sweden). The MDD

diagnosis was confirmed by a psychiatrist according to M.I.N.I. Patients with MADRS>20

without ongoing antidepressant treatment and medical history free from CNS or somatic

diseases (N=8) received escitalopram 10mg/day for 8 weeks. MADRS was recorded before

treatment initiation, and treatment response was evaluated after 3-4 and 6-7 weeks treatment with escitalopram (Gärde et al., 2024). Actigraphy recordings were acquired using actigraphs (Actiwatch 2, Philips Respironics, Murrysville, PA, USA) worn on the wrist of the non-dominant arm for ~1 week before treatment initiation, and after 3 weeks of escitalopram treatment. (3) a study on the effects of ketamine on serotonin 1B receptor binding in patients with selective serotonin reuptake inhibitors (SSRI) resistant depression (Tiger et al., 2020) (Ethical Permit No. 2017/799-31, Swedish Ethical Review Authority; pre-registration: AsPredicted.org #17602). The study recruited by internet-based advertisements, and included patients with an ongoing major depressive episode (according to M.I.N.I.), with MADRS ≥ 20, resistant to SSRI treatment in an adequate dose for at least 4 weeks. Ongoing antidepressant treatment was discontinued and actigraphy data was collected after a washout period of at least 5 times the half-life of the SSRI. The patients were instructed to wear the actigraph (Actiwatch 2, Philips Respironics, Murrysville, PA, USA) continuously on the wrist of the non-dominant arm and not remove it unless for personal safety reasons. The recording started prior to the first ketamine or placebo infusion and continued for the duration of the open-label ketamine treatment program (0.5mg/kg, 2 infusions/week for 2 weeks; placebo N=10, ketamine N=20) (Tiger et al., 2020). Basic demographics, including the number of subjects included from each study are depicted in Table 1. Preliminary analyses did not identify significant differences between male and female subjects in individual features, symptom severity, or response to MDD treatment, therefore sex was not included in further analyses. The data available in the three cohorts allowed alternative partitioning into "before treatment" (MDD, pooled N=35), which was used as reference for all subsequent comparisons involving subjects on antidepressive treatments. Similarly, all subjects with MADRSpost ≤ 10 were assigned to a single group "remission" (pooled N=12, including iCBT, N=3; escitalopram, N=2; ketamine, N=7).

The timing of actigraphy recording and MADRS evaluations are depicted in Fig. 1A, and the number of days of actigraphic recordings are depicted in Supplementary Table 1. Actigraphic recordings on patients receiving iCBT as MDD treatment were acquired using GENEActiv Original wrist-worn actigraphs (ActivInsights, Cambs, UK). The devices use three-dimensional accelerometers (dynamic range up to 8g; 12-bit encoding, resolution 3.9 mg) at 30 Hz sampling rate to record wrist movement. The raw data was downloaded using proprietary software, then processed in MATLAB (The Mathworks, Natick, MD, USA), using a modified version of the code (https://github.com/DavidRConnell/geneactivReader), as

described earlier (Ekholm et al., 2020). Briefly, the Euclidean norm of change in acceleration

vector was first smoothed using a rolling Gauss window spanning 30 consecutive datapoints

(1s), then a high-pass filter was applied (threshold: 20 mg = 196 mm/s^2) before computing the

sum of changes in acceleration vectors over 1 min epochs (1440 samples/24h). Actigraphic

recordings on patients receiving escitalopram or ketamine as antidepressant treatment were

acquired using Actiwatch 2 wrist-worn devices (Philips Respironics, Murrysville, PA, USA)

set to record activity only integrated over 1 min epochs. The raw data was downloaded

according to manufacturer's instructions (Actiware 6.x, Philips Respironics) then exported as

text files. The text file was imported to MATLAB using a custom function designed to yield

an output similar to the one generated by the import function for GENEActiv devices.

Quality control and inclusion criteria

The quality control was performed by the same observer, blind to group belonging. All

recordings were first inspected visually using a standardized procedure designed to identify

stretches of missing data, artifacts, and gross abnormal circadian patterns of activity (*e.g.*,

shift work, or other consistent activity at night). Intervals containing suspected shift work (not

reported at the time of recording), potential artifacts, or missing data, were cropped out. Only

recordings spanning at least 3 consecutive days were included in further analyses.

Pre-processing and feature extraction

All processing of actigraphy data was performed in MATLAB. The data import procedures

yielded sizeable differences in range of raw output (activity/min) between GENEActiv and

Actiwatch 2 devices, but the coefficient of variability of individual days was similar across

devices (see Supplementary Fig. S1). These differences were managed in the design of feature

extraction procedures as follows: (1) no features relying on absolute magnitude values were

included; and (2) features such as circadian peak and trough were calculated after mean

normalization of raw data. We first cropped all recordings between the first and the last

recorded midnight to yield an integer number of 24-h periods. For each subject we applied the

feature extraction procedures on individual days and on circadian profiles calculated as the

average across corresponding time bins of registered individual days. The features calculated

on individual days were used for estimation of variability across days.

The features we extracted describe the regularity, fragmentation, and complexity of circadian

patterns of activity, and uses custom implementations of publicly available algorithms. The

complete list of features and their calculations is available in Supplementary Table 2. The

following features were extracted: circadian period; circadian peak and trough; relative
amplitude (Ekholm et al., 2020; Gonçalves et al., 2015; Lyall et al., 2018); scaling exponents
(Hu et al., 2004); intradaily variability (IV); interdaily stability (IS) (Gonçalves et al., 2014);
day-to-day variability, and propensity to sustain activity.

Circadian period was estimated using the Lomb-Scargle algorithm optimized for MATLAB
implementation (Saragiotis, 2021). The Lomb-Scargle periodogram was preferred over the
commonly used Sokolove-Bushell algorithm (Sokolove and Bushell, 1978) because the latter
has been shown to yield period estimates biased towards periods below 24 h (Tackenberg and
Hughey, 2021). The circadian period was calculated over the entire recording using an
oversampling factor of 10 to yield resolution of the estimated in the range of minutes. The
scaling exponent for detrended fluctuation analysis was calculated for the magnitude of
measured activity in 1-min bins using boxes equally spaced on a logarithmic scale between 4
min (4 consecutive samples) and 24 h (1440 consecutive samples) as described by Hu et al.
(Hu et al., 2004). The scaling exponent is a feature of the intrinsic regulatory mechanisms
controlling the rest/activity patterns. It has not been shown to be sensitive to extrinsic factors
the subject is exposed to in normal daily activity, but is altered as a result of disease
(Chapman et al., 2017; Fasmer et al., 2016; Hu et al., 2004). Intradaily variability (IV)
estimates the fragmentation of activity patterns by calculating the ratio between mean squared
differences between consecutive time intervals and the mean squared difference from global
mean activity per interval; it increases as the frequency and the magnitude of transitions
between rest and active intervals increase, and decreases as the active and inactive intervals
consolidate (Gonçalves et al., 2015). Interdaily stability (IS) evaluates the coupling between
activity patterns and circadian entrainers and is calculated as the ratio between variability
around circadian profile and global variability. High values indicate consistent activity
patterns across days, consistent with strong coupling between activity and circadian
entrainers. The relative amplitude of circadian rhythms of activity (RA) estimates the
robustness of average circadian rhythms (Edgar and McClung, 2013; Lyall et al., 2018). The
range of RA is bounded between 0 (no circadian rhythms) and 1 (robust circadian rhythms,
with consistent timing of consolidated rest interval longer than 5 h across days). The day-to-
day variability comprised 3 features as follows: circadian profile variance between
consecutive days (SeqVar), calculated as Euclidean distance between consecutive days,
normalized to the total number of samples per day; variation from average circadian profile
(ProfileVar), calculated as the Euclidean distance between each day and the average profile,

normalized to the total number of samples per day; and the normalized difference between

consecutive days (SeqProfileVar), calculated as the ratio between mean difference between

circadian profiles of consecutive days and mean deviation from average circadian profile. The

propensity to sustain activity (SustainProp) was calculated as the slope of likelihood to sustain

or increase activity in the next minute against current level of activity. The distribution was

calculated for minutes with activity count>10 (which eliminated the range specific for sleep,

~30% of datapoints/day) in 20 equally spaced bins covering the range up to the 99th percentile

of active minutes. This is a hybrid measure applying a sequence-based analysis on the

distribution of activity counts/min (assumed to have exponential distribution). The likelihood

to further increase activity drops with increasing the activity counts in the current minute,

therefore the slope is negative, and approaches 0 at the right tail of the distribution. A shallow

slope indicates the subject is unlikely (not willing) to sustain even low levels of activity. For

scrambled data (preserved distribution, but random sequence), the slope is about -0.3

(likelihood to sustain activity decreases by 30% when the activity count increases 10-fold).

Feature selection

There is virtually no consensus around the analysis of actigraphy and parameter selection for

feature extraction. Therefore, the initial feature space included a number of features with

different degrees of similarity, as illustrated by the matrix of correlations in Supplementary

Fig. S2. To mitigate the impact of multicollinearity, one can choose between dimensionality

reduction techniques (*e.g.*, PCA, UMAP), and feature selection. The former has the advantage

of identifying latent structures in the feature space and accurately accounting for underlying

patterns in downstream calculations, but the analysis of individual feature contribution is not

straightforward. The latter facilitates the intuitive interpretation of the final result, but carries

the risk of missing out on underlying latent structures. We opted for feature selection to take

advantage of the interpretability of the results. This is particularly relevant for Bayesian

model averaging, where posterior inclusion probability is artificially deflated by including

highly correlated features. The initial feature space included 90 features, distributed in 4

overlapping clusters as follows: circadian profiles; mean daily features; daily variability

around the average; and sequential daily variability. Day-to-day variability (calculated as the

ratio between mean squared sequential differences in circadian profile and the mean squared

difference from average profile) could only be calculated on the full recording and was

assigned to the first cluster. We used a hybrid (heuristic and data driven) approach for feature

selection, focusing on reducing the clusters of conceptually related features which were highly

correlated in healthy controls and MDD patients before treatment (see Supplementary Fig. S3). The correlation patterns yielded by features calculated on circadian profiles largely matched the correlations among features calculated on single days. In addition, the correlations between variability around the average and sequential variability were virtually perfect, rendering the 2 sets redundant. The final feature space consisted of 28 features, including 12 from the circadian profile cluster and their correspondents in daily variability around the average; propensity to sustain activity and its variance across days; day-to-day variability of circadian profile; and subject age (Supplementary Table 2).

Effects of antidepressive treatments and correlations with response to treatment

The design of analysis uses several underlying assumptions. (1) The effect of antidepressant treatment is assumed to have reached steady state at the time of recording, and no features exhibit significant drifting. This was verified by inspection of trends in individual features for each subject (not shown). (2) MADRS evaluation reflects an average state spanning the best part of the recording period. The self-assessment MADRS scale requires the subject to evaluate the severity of symptoms over the last 3 days, and it is therefore justifiable to assume irrelevant changes over a period of 5-7 days around the time of evaluation. (3) The pharmacological effects are stable on both mood and circadian regulation of activity. Classical antidepressive treatments take a couple of weeks to exert significant effects on mood (*i.e.*, iCBT and escitalopram), which is then stable for sufficiently long time for the purpose of actigraphy recording. Fast-acting antidepressants (*i.e.*, ketamine), induce measurable effects on mood within a couple of hours after administration. The regimen of ketamine administration in the cohort analyzed here was designed to ensure stable drug effect covering 2 weeks in the open-label phase of the study.

The response to treatment was calculated as relative change from baseline MADRS. The MADRS scores used for the estimation of response to treatment were the last measurement available before starting the treatment (baseline), and the last measurement available after treatment initiation (see also Fig. 1C, D for details).

Ensemble training and Bayesian model averaging

We implemented an ensemble approach to fit the response to treatment, as described earlier (Spulber et al., 2025). The training was performed independently for 3 groups: iCBT, ketamine, and any treatment (iCBT, ketamine, or escitalopram). We have generated the initial ensemble by independent homogenous training using a systematic bootstrapping (with

replacement) scheme for selecting up to 6 features/model (systematic testing of all possible

combinations of features). This approach ensured a minimum of 2 subjects/feature for the

iCBT cohort (N=12). The number of subjects available in the escitalopram cohort (N=7) was

too low to train meaningful models, therefore the response to escitalopram was not modeled

independently. After training, we applied an adaptation of Occam's window algorithm

(Madigan and Raftery, 1994; Raftery et al., 1997). First, we included all models satisfying the

following criteria: VIF<5 (to avoid multicollinearity issues); and adjusted R-square>0.2

(adjusted R-square>0.1 for "any treatment" ensemble). Next, we excluded all models

receiving less support from the data than their simpler submodels. More complex models

(using *n* features) which are less accurate than other any of the less complex models trained

on the same subset of features (using any combination of *n-1* features) were excluded. This

procedure penalizes more complex models if their accuracy is not superior to simpler models.

The pruned ensembles were then sorted by increasing RMSE (decreasing accuracy) and the

aggregated output of each ensemble was calculated as the cumulative Bayesian average of

individual models for each subject, using the inverse model RMSE as weights (Raftery et al.,

1997).

We applied a Bayesian approach for the analysis of coefficients in the pruned ensembles.

First, we estimated the prior inclusion probability for an individual feature as the proportion

of models including a specific feature relative to the total number of models possible to train

under the constraint of maximum 6 features/model to 0.2035 (see Supplementary Material).

The posterior inclusion probability (PIP) for each feature was calculated as the frequency of

occurrence in the pruned ensembles, and was used for defining levels of evidence strength as

follows: PIP>0.2035 identifies features with frequency of occurrence increased as compared

to initial probability (enriched), and indicates medium to strong evidence of correlation; in

contrast, PIP < prior inclusion probability denotes features depleted after pruning, and

indicates weak evidence of correlation. The effect size for individual features was estimated

as the average of standardized coefficients across all models in the pruned ensemble. Lastly,

we calculated the coefficient of variation (CV=standard deviation/average) for standardized

coefficients to estimate the stability of individual features (context-independence).

Results

Individual features are differentially affected by MDD treatments

We first evaluated the differences between healthy controls and MDD subjects at population

level. Given the differences in inclusion criteria between the ketamine study (insufficient

response to SSRI (Tiger et al., 2020)) and the iCBT trial, we evaluated the potential selection

bias between the two populations before pooling the data. Sparse between-group differences

surviving FDR correction (variability of circadian profile and scaling exponent for short

intervals; see Supplementary Fig. S4) did not justify the stratification of MDD patients before

treatment into distinct populations. We did not find significant differences between pooled

MDD patients before treatment and healthy controls (Fig. 2A). The analysis of the effects of

MDD treatments on activity patterns, independently from the magnitude of response,

highlighted significant effects on a wide range of features, with distinct, non-overlapping

signatures across treatments (Fig. 2A). This approach assumed that MDD treatments,

including non-pharmacological intervention (iCBT) and antidepressant drugs (escitalopram,

ketamine) may impact circadian regulation of activity independent of antidepressant effects

(reviewed in (Kiehn et al., 2019; Silva et al., 2021)). The effects can be summarized as

follows: the variability of circadian profile of activity increase in subjects undergoing iCBT.

Under escitalopram treatment, the patterns of activity are less variable within the day (lower

scaling exponents for short intervals, decreased variability in IV5 and scaling exponent for

short intervals), more consistent across days (stronger circadian entrainment, *i.e.*, stable

alignment to the 24h light-dark cycle: higher RA and IS30), and the subjects display a higher

propensity to sustain activity as compared to untreated MDD subjects. Under ketamine

treatment, the patterns of activity are more fragmented (increased IV5), less complex

(decreased scaling exponents), and more variable across days (increased circadian profile

variability) as compared to untreated MDD subjects. Lastly, comparisons between subjects in

remission (regardless the antidepressive treatment leading to remission) and healthy controls

or MDD patients before treatment yielded no significant differences for any single feature

(Fig. 2A).

Next, we evaluated the correlations between the magnitude of response to treatment and

longitudinal changes in individual features of activity (Fig. 2B). In subjects treated by iCBT,

we did not find significant correlations between the magnitude of response to treatment and

changes in individual features, while drug treatments displayed sparse significant correlations

with individual features. In subjects treated with escitalopram, better response correlated with

increase in circadian peak of activity, decrease in fragmentation of activity, and decrease in

propensity to sustain activity. In subjects treated with ketamine infusions, better response to

treatment correlated with a shift in location of circadian peak of activity towards earlier

occurrence. When all treatments were pooled, better response to treatment was associated

with a shift in location of circadian peak of activity towards earlier occurrence, and a

stabilization of circadian rhythms (illustrated by decreased daily variability of IS30).

Distinct signatures in correlations between magnitude of response and individual features for

different MDD treatments

We asked whether features of activity patterns during the depressive episode (before initiating

any antidepressive treatment) correlate with the magnitude of response to treatment, and

whether the correlations are treatment-specific. When each antidepressive treatment was

analyzed separately, we found distinct patterns for iCBT, escitalopram, and ketamine (Fig.

3A). For iCBT, better response was associated with higher age, steeper propensity to sustain

activity, higher variability in location of circadian trough, and weaker circadian entrainment

(lower IS30 and higher vIS30). For escitalopram we did not find correlation surviving

correction for FDR, but we observed a trend in correlation between response to treatment and

lower variability in fragmentation of activity patterns. Better response to ketamine was

associated with increased variability in magnitude of circadian peak of activity. When all

cohorts were pooled, better response to treatment was associated with more stable patterns of

activity before treatment, as illustrated by decreased variability in location of circadian peak

as well as in scaling exponent (Fig. 3A).

We next asked whether the response to treatment can be modeled by linear combinations of

features. To this end, we trained 3 independent ensembles of multiple linear regression

models to fit the response to treatment for iCBT and ketamine separately, and used the pooled

dataset for fitting the response to treatment irrespective of treatment group ("any treatment").

The pruned ensembles consisted of 41768, 18178, and 23223 models for iCBT, ketamine, and

any treatment, respectively (Fig. 3B). To analyze the performance of each ensemble, we

sorted the models by decreasing accuracy (increasing RMSE), then calculated the accuracy of

ensemble fitting (aggregated output) in a cumulative fashion (Fig. 3C). The aggregated

accuracy of all ensembles outperformed independent models, and the accuracy changed with

increasing the number of models included in a non-monotonic manner: the initial

improvement in accuracy was followed by gradual degradation with different rates for each

ensemble (Fig. 3C). Notably, the ensemble fitting the response to any treatment had an

accuracy considerably lower than the ensembles fitting the response to either iCBT or

ketamine. This is illustrated by the range of variation for aggregated RMSE (minimum:

0.1377 for any treatment, vs. 0.0085 for iCBT and 0.0572 for ketamine; maximum: 0.1588 for

any treatment, vs. 0.0496 for iCBT and 0.1092 for ketamine; Fig. 3C). For a MADRS score of

30 before treatment, this translates into an expected error in prediction of MADRS score after

treatment between 0.25 and 1.5 for iCBT; 1.7 and 3.3 for ketamine; and 4.1 and 4.8 for any

treatment.

To investigate the biological relevance of modeling the response to treatment, we performed a

Bayesian analysis of coefficients. The contribution of individual features in ensembles

presumably changes depending on the context (*i.e.*, all other features included in the model),

and the importance of variables in the model can be assessed using several approaches

(Grömping, 2015). We described the contribution of individual features using the following

parameters: PIP (*i.e.*, frequency of inclusion in the pruned ensemble, to identify the most

relevant features); mean standardized coefficient (to estimate effect magnitude); and

coefficient of variance (to estimate the context-dependence for each coefficient) (Fig. 4A; see

also Supplementary Fig. S5). These three measurements are not necessarily orthogonal, but

their joint analysis highlights the individual contribution of most relevant features. For each

ensemble we found enriched features (PIP>0.2035) also had low variability, with limited

overlap across ensembles (Fig. 4B). The mean standardized coefficients for individual

features varied considerably across ensembles, and filtering the feature space by CV or PIP

yielded distinct signatures across ensembles (Fig. 4B; see also Supplementary Fig. S6).

Further analyses focused on subsets of enriched features for each ensemble (Fig. 4B and

Supplementary Fig. S6). The pattern of correlations between individual features before

treatment and the response to treatment can be summarized as follows: better response to

iCBT correlated with higher age, weaker circadian entrainment (low IS30, high vM10s, vL5L,

vIS30, variability of circadian profile), earlier circadian peak of activity (M10L), and steeper

propensity to sustain activity; better response to ketamine correlated with higher age, stronger

circadian entrainment (high RA, vM10s, but lower vL5L), higher fragmentation of activity

patterns (high IV5), and steeper propensity to sustain activity; and better response to any

treatment correlated with higher age, more robust circadian rhythms (high RA), lower and

more variable circadian peak of activity (low M10s, high vM10s), and steeper propensity to

sustain activity.

To further explore the differences between the ensembles modeling the response to iCBT or

ketamine we used a scatterplot to map the contributions of individual features as measured by

the standardized coefficients (Fig. 4C). The mapping of enriched features across the quadrants

highlighted the distinct contributions of relevant features to modeling the response to

treatment: differentially enriched features had larger effects in the ensemble they were

enriched in. Out of the 5 features found to be enriched in both ensembles, variability in

location of circadian trough and variability in circadian profile had similar effects; while age,

variability in circadian peak amplitude, and propensity to sustain activity had opposite effects.

Discussion

In this study we visualize the impact different MDD treatment alternatives have on circadian

patterns of activity. This was possible thanks to the development of a data analysis pipeline,

including pre-processing, feature extraction and feature selection for actigraphy recordings as

objective measurement. We identified only sparse correlations between individual features

measured during a depressive episode and the response to specific MDD treatments, which

yielded distinct signatures for each treatment alternative. When the response to treatment was

modeled by combinations of features, the Bayesian analysis of coefficients highlighted

differences and similarities between contributions of specific features to modelling the

response to iCBT or ketamine.

We did not find differences between MDD subjects and healthy controls for individual

features, neither before treatment, nor in remission after treatment. MDD is a disease with

largely unknown etiology and heterogenous manifestations (according to diagnostic criteria

listed in DSM-5[36], 1497 possible combinations of symptoms can lead to a an MDD

diagnosis)(Østergaard et al., 2011), and the diversity within the MDD patient population can

confuse comparisons against healthy controls. A large population-based study found that

circadian rhythm features (relative amplitude of activity intensity or skin temperature) do not

display sex-dependent differences, and have small effect on predicting the diagnosis for mood

disorders (Brooks et al., 2021). Similarly, we did not find sex-related differences between

groups, nor did we find significant differences between MDD subjects and healthy controls.

The ketamine cohort may be assumed fundamentally different from the iCBT and

escitalopram cohorts since it was restricted to MDD patients with resistance to SSRI treatment

(Tiger et al., 2020). However, we found only sparse differences among cohorts before

treatment, which could be related to differences between subgroups being obscured by the

overall heterogeneity of the MDD population. In addition, the fact that the healthy controls

were matching only the MDD patients in the iCBT cohort, stratification by sex or cohort

would not be meaningful when comparing MDD patients against healthy controls.

The analysis of effects of treatment on circadian patterns of activity yielded treatment-specific

signatures: iCBT increases variability of circadian profile; escitalopram strengthens circadian

entrainment; and ketamine weakens circadian entrainment. For iCBT as non-pharmacological

intervention, the patient is supposed to gradually change behavior in a voluntary manner

(Weitz et al., 2015). MDD patients undergoing CBT display increased serotonin transporter

availability in a composite region including parts of the limbic system (amygdala, cingulate

cortex, hippocampus), basal ganglia (caudate and putamen), insular cortex, and thalamus

(Svensson et al., 2021), as well as reduced blood concentrations of purine metabolites and

increased concentration of branched aminoacids (Bhattacharyya et al., 2024). Alterations in

activity patterns can be expected, but there are no definite molecular mechanisms. Circadian

entrainment is dependent on the central clock, located in the suprachiasmatic nucleus (SCN)

in the anterior hypothalamus, and most neurotransmitter systems on which antidepressants act

have been shown to impact circadian rhythms (recently reviewed in (Daut and Fonken, 2019;

Lee et al., 2022; Sato et al., 2022)). The effects we observed are in agreement with theoretical

pharmacological mechanisms. Serotonin tonically inhibits the direct input from retinal

ganglionic neurons, and blocking serotonin reuptake weakens photic entrainment of the SCN

(reviewed in (Ciarleglio et al., 2011)). Therefore, blocking photic input to the SCN would

simplify the internal clock function, which can explain the strengthening of circadian

entrainment we observed in MDD subjects treated with escitalopram. Ketamine has been

shown to directly interfere with clock gene transcriptional activity in primary fibroblasts

(Bellet et al., 2011), and appears to have widespread suppressive effects on circadian clock

machinery (Sato et al., 2022). When applied to the SCN function, two main alterations are

expected in patients treated with ketamine: (1) weaker circadian entrainment of activity; and

(2) disorganized patterns of activity (see (Hu et al., 2007)). Remarkably, both effects were

observed in our cohort. While the pharmacological effects appear consistent at group level,

the response ranges from negligible to remission for each treatment. Therefore, we looked for

within-patient changes which correlate with "good response". As expected, the response to

specific treatments correlate with changes in different features, but when all cohorts were

pooled together, changes in two specific features correlate with the magnitude of response

(timing of circadian peak of activity, and variability in circadian entrainment) suggest that

stronger circadian entrainment of activity correlates with better response to MDD treatment.

In addition, we found that better response correlates with a shift towards earlier occurrence of

circadian peak, in agreement with previous reports (Duncan et al., 2017). This points to

circadian entrainment of activity being a relevant endpoint for evaluation of response to

treatment in MDD subjects, regardless of the antidepressive treatment followed.

We have shown earlier that patterns of activity can be reliably used for modeling symptom

severity before treatment (Spulber et al., 2022), and here we hypothesized that the response to

treatment, estimated as relative change from baseline, can be modeled using features of

circadian patterns of activity during the depressive episode (before treatment initiation). This

approach has two potential pitfalls: (1) it does not account for variations in individual items in

the MADRS scale; and (2) it ignores all intermediate states between before and after

treatment. Regarding the former, it has been shown that the underlying variability is rather

limited (Catarino et al., 2022; Rabinowitz et al., 2019; Rabinowitz and Rabinowitz, 2022;

Simmonds-Buckley et al., 2021), which makes the total score a robust estimator of current

state. We then assumed that symptom severity was reasonably stable (plateau) around the

time of recording. The dynamics of response to treatment varies considerably among MDD

treatments, but it has been shown to be approximated by an exponential decay (Taliaz et al.,

2021). For iCBT, the response appears linear (see (Svensson et al., 2021)), and the response is

most reliably evaluated at the end of the course (10 weeks). The response to SSRIs has been

described as either fast (stable response is reached within 2 weeks after treatment onset), or

slow (symptom severity decreases slowly after an initial plateau), but it is either way stable

after 6 weeks of treatment (Fiori et al., 2021). In contrast, a rapid decrease in symptom

severity can be documented within hours after a single dose of ketamine administration,

followed by a stable response lasting a couple of days (Berman et al., 2000; Sato et al., 2022).

We believe that the investigation of correlations between patterns of activity, as expression of

current status, and the response to treatment, as change driven by therapeutic intervention, is a

meaningful approach, provided the interval between measurements is appropriate for the

actual treatment (*i.e.*, 10-12 weeks for iCBT; ~6 weeks for SSRIs; and ~2 weeks for

ketamine). We have modeled the response to treatment independently from timeline of

transition between plateaus using parallel training of linear regression models, then used

Bayesian model averaging to account for model uncertainty and increase the generalizability

of the findings (Astuti et al., 2014; Raftery et al., 1997). The added value of Bayesian analysis

of coefficients is to support the high-level interpretation of correlations between patterns of

activity and response to treatment: the standardized coefficients for the subset of enriched

features can be translated into behavioral phenotyping of MDD patients who would benefit

most from a specific MDD treatment. MDD subjects with weaker circadian entrainment,

would have better response to iCBT. However, MDD patients undergoing iCBT appear to

increase circadian profile variability, which can be interpreted as weakening of circadian

entrainment. Similarly, MDD subjects with fragmented daytime activity would have better

response to ketamine, while ketamine treatment increases fragmentation of activity. Taken
together, our data indicate that positive effects of specific antidepressive treatment are not
necessarily associated with measured changes towards "normalization" of activity patterns
(*i.e.*, reverse the deviations from healthy controls). Our data suggest potential prospective
applications for predicting the response to specific MDD treatments. However, the
generalizability of our findings needs to be tested prospectively on independent datasets.

In conclusion, we identified distinct signatures in the correlations between patterns of activity
and response to specific MDD treatments. We further found that the stabilization of circadian
entrainment correlates with the magnitude of response independently from the antidepressive
treatment followed. Our data suggests that the analysis of circadian patterns of activity may
potentially be used for predicting the response to treatment in MDD patients, but larger
confirmatory studies are required to support clinical applications.

Acknowledgments

The authors would like to thank Prof. Matteo Bottai (Division of Biostatistics, Karolinska
Institutet) for inspiring discussions and suggestions for planning the analyses. Hardware and
support for actigraphy data collection was provided by the Ass. Prof. Viktor Kaldo
(Department of Psychology, Karolinska Institutet) and Philips (Philips Healthcare, Sleep and
Respiratory Care, Murrysville, PA, USA).

Author contributions

Conceptualization SS, FE, SC, JL. Data curation SS, MG, MT, JL. Formal Analysis SS, FE.
Funding acquisition SC, MT, JL. Investigation SS, FE, MG, MT, JL. Methodology SS, FE,
MT, JL. Project administration MT, SC, JL. Resources SC, MT, JL. Software SS. Supervision
SS, SC, MT, JL. Validation SS, SC, MT, JL. Visualization SS, FE. Writing – original draft
SS, FE. Writing – review & editing SS, FE, SC, MG, MT, JL.

Funding

Funding to support the work was provided by Swedish Society of Medicine, Fredrik and
Ingrid Thuring Foundation, Region Stockholm (ALF project 20190429, and clinical research
appointment), The Swedish Brain Foundation (Hjärnfonden), and The Söderström König
Foundation (SLS-746501) (MT); Swedish Research Council (2013-09304), Region
Stockholm (ALF project 20170192 and higher clinical research appointment) (JL); Swedish
Research Council (2019-01191), The Swedish Brain Foundation (Hjärnfonden, FO2016-
0116), and Torsten Söderberg Foundation (M59/16) (SC); and Karolinska Institutet research

grants (MT, SC, JL). The funding agencies and sponsors did not have any influence on the

conceptualization, design, data collection, analyses, decision to publish, or preparation of the

manuscript.

Competing interests

The research leading up to the present work generated US Patent No. 10,731,216 – Methods

and compositions for biomarkers of depression and pharmacoresponse (SC and SS inventors).

The patent is owned by NorthernLight Diagnostics AB (SC and SS co-founders), a company

developing decision support tools for mental health care. The company did not provide

funding and was not involved in the present study. The other authors declare no competing

interests.

References

Astuti, A.B., Iriawan, N., Kuswanto, H., 2014. Model Components Selection in Bayesian
Model Averaging Using Occam's Window for Microarray Data. Journal of Scientific
Modeling & Computation 1.
Athreya, A.P., Brückl, T., Binder, E.B., John Rush, A., Biernacka, J., Frye, M.A., Neavin, D.,
Skime, M., Monrad, D., Iyer, R.K., Mayes, T., Trivedi, M., Carter, R.E., Wang, L.,
Weinshilboum, R.M., Croarkin, P.E., Bobo, W. V., 2021. Prediction of short-term
antidepressant response using probabilistic graphical models with replication across
multiple drugs and treatment settings. Neuropsychopharmacology 46, 1272–1282.
https://doi.org/10.1038/S41386-020-00943-X
Bellet, M.M., Vawter, M.P., Bunney, B.G., Bunney, W.E., Sassone-Corsi, P., 2011. Ketamine
Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression.
PLoS One 6, 23982. https://doi.org/10.1371/journal.pone.0023982
Berman, R.M., Cappiello, A., Anand, A., Oren, D.A., Heninger, G.R., Charney, D.S., Krystal,
J.H., 2000. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47,
351–354. https://doi.org/10.1016/S0006-3223(99)00230-9
Bhattacharyya, S., Mahmoudian Dehkordi, S., Sniatynski, M., Belenky, M., Marur, V., Rush,
J., Craighead, E., Mayberg, H., Dunlop, B., Kristal, B., Kaddurah-Daouk, R., Mood
Disorder Precision Medicine Consortium, 2024. Metabolomics Signatures of serotonin
reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor
(Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in
Major Depressive Disorder. MedRxiv. https://doi.org/10.1101/2024.04.02.24304677
Brooks, T.G., Lahens, N.F., Grant, G.R., Sheline, Y.I., FitzGerald, G.A., Skarke, C., 2021.
Phenome-Wide Association Study of Actigraphy in the UK Biobank. medRxiv.
https://doi.org/10.1101/2021.12.09.21267558
Browning, M., Kingslake, J., Dourish, C.T., Goodwin, G.M., Harmer, C.J., Dawson, G.R.,
2019. Predicting treatment response to antidepressant medication using early changes in
emotional processing. European Neuropsychopharmacology 29, 66–75.
https://doi.org/10.1016/j.euroneuro.2018.11.1102
Carlbring, P., Andersson, G., Cuijpers, P., Riper, H., Hedman-Lagerlöf, E., 2017. Internet-
based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders:
an updated systematic review and meta-analysis.
https://doi.org/10.1080/16506073.2017.1401115

Catarino, A., Fawcett, J.M., Ewbank, M.P., Bateup, S., Cummins, R., Tablan, V., Blackwell,
A.D., 2022. Refining our understanding of depressive states and state transitions in
response to cognitive behavioural therapy using latent Markov modelling. Psychol Med
52, 332–341. https://doi.org/10.1017/S0033291720002032
Chapman, J.J., Roberts, J.A., Nguyen, V.T., Breakspear, M., 2017. Quantification of free-
living activity patterns using accelerometry in adults with mental illness. Sci Rep 7, 1–
12. https://doi.org/10.1038/srep43174
Ciarleglio, C.M., Resuehr, H.E.S., McMahon, D.G., 2011. Interactions of the serotonin and
circadian systems: nature and nurture in rhythms and blues. Neuroscience 197, 8–16.
https://doi.org/10.1016/J.NEUROSCIENCE.2011.09.036
Daut, R.A., Fonken, L.K., 2019. Circadian regulation of depression: A role for serotonin.
Front Neuroendocrinol 54, 100746. https://doi.org/10.1016/J.YFRNE.2019.04.003
Duncan, W.C., Slonena, E., Hejazi, N.S., Brutsche, N., Yu, K.C., Park, L., Ballard, E.D.,
Zarate, C.A., 2017. Motor-Activity Markers of Circadian Timekeeping Are Related to
Ketamine's Rapid Antidepressant Properties. Biol Psychiatry 82, 361–369.
https://doi.org/10.1016/J.BIOPSYCH.2017.03.011
Edgar, N., McClung, C.A., 2013. Major depressive disorder: a loss of circadian synchrony?
Bioessays 35, 940–4. https://doi.org/10.1002/bies.201300086
Ekholm, B., Spulber, S., Adler, M., 2020. A randomized controlled study of weighted chain
blankets for insomnia in psychiatric disorders. Journal of Clinical Sleep Medicine 16,
1567–1577. https://doi.org/10.5664/jcsm.8636
Fasmer, O.B., Hauge, E., Berle, J.Ø., Dilsaver, S., Oedegaard, K.J., 2016. Distribution of
active and resting periods in the motor activity of patients with depression and
schizophrenia. Psychiatry Investig 13, 112–120. https://doi.org/10.4306/pi.2016.13.1.112
Fiori, L.M., Orri, M., Aouabed, Z., Théroux, J.F., Lin, R., Nagy, C., Frey, B.N., Lam, R.W.,
MacQueen, G.M., Milev, R., Müller, D.J., Parikh, S. V., Rotzinger, S., Uher, R., Foster,
J.A., Kennedy, S.H., Turecki, G., 2021. Treatment-emergent and trajectory-based
peripheral gene expression markers of antidepressant response. Translational Psychiatry
2021 11:1 11, 1–8. https://doi.org/10.1038/s41398-021-01564-8
Gärde, M., Matheson, G.J., Varnäs, K., Svenningsson, P., Hedman-Lagerlöf, E., Lundberg, J.,
Farde, L., Tiger, M., 2024. Altered Serotonin 1B Receptor Binding After Escitalopram
for Depression Is Correlated With Treatment Effect. International Journal of
Neuropsychopharmacology 27, 21. https://doi.org/10.1093/IJNP/PYAE021
Gonçalves, B., Adamowicz, T., Louzada, F., Moreno, C., Araujo, J., 2015. A fresh look at the
use of nonparametric analysis in actimetry. Sleep Med Rev 20, 84–91.
https://doi.org/10.1016/j.smrv.2014.06.002
Gonçalves, B.S.B., Cavalcanti, P., Tavares, G.R., Campos, T.F., Araujo, J.F., 2014.
Nonparametric methods in actigraphy: An update. Sleep Science 7, 158–164.
https://doi.org/10.1016/j.slsci.2014.09.013
Grömping, U., 2015. Variable importance in regression models. Wiley Interdiscip Rev
Comput Stat 7, 137–152. https://doi.org/10.1002/WICS.1346
Helgadóttir, B., Forsell, Y., Ekblom, Ö., 2015. Physical Activity Patterns of People Affected
by Depressive and Anxiety Disorders as Measured by Accelerometers: A Cross-
Sectional Study. PLoS One 10, e0115894. https://doi.org/10.1371/journal.pone.0115894
Hu, K., Ivanov, P.Ch., Chen, Z., Hilton, M.F., Stanley, H.E., Shea, S.A., 2004. Non-random
fluctuations and multi-scale dynamics regulation of human activity. Neuroscience 149,
508–517. https://doi.org/10.1016/j.physa.2004.01.042.Non-random
Hu, K., Scheer, F.A.J.L., Ivanov, P.C., Buijs, R.M., Shea, S.A., 2007. The suprachiasmatic
nucleus functions beyond circadian rhythm generation. Neuroscience 149, 508–17.
https://doi.org/10.1016/j.neuroscience.2007.03.058

Kang, S.J., Leroux, A., Guo, W., Dey, D., Strippoli, M.P.F., Di, J., Vaucher, J., Marques-
Vidal, P., Vollenweider, P., Preisig, M., Merikangas, K.R., Zipunnikov, V., 2024.
Integrative Modeling of Accelerometry-Derived Sleep, Physical Activity, and Circadian
Rhythm Domains With Current or Remitted Major Depression. JAMA Psychiatry 81,
911–918. https://doi.org/10.1001/JAMAPSYCHIATRY.2024.1321
Khan, A., Faucett, J., Lichtenberg, P., Kirsch, I., Brown, W.A., 2012. A Systematic Review of
Comparative Efficacy of Treatments and Controls for Depression. PLoS One 7, e41778.
https://doi.org/10.1371/journal.pone.0041778
Kiehn, J.-T., Faltraco, F., Palm, D., Thome, J., Oster, H., 2019. Circadian Clocks in the
Regulation of Neurotransmitter Systems. Pharmacopsychiatry. https://doi.org/10.1055/a-
1027-7055
Krystal, J.H., Abdallah, C.G., Sanacora, G., Charney, D.S., Duman, R.S., 2019. Ketamine: A
Paradigm Shift for Depression Research and Treatment. Neuron 101, 774–778.
https://doi.org/10.1016/J.NEURON.2019.02.005
Lee, R., McGee, A., Fernandez, F.-X., 2022. Systematic review of drugs that modify the
circadian system's phase-shifting responses to light exposure.
Neuropsychopharmacology 47, 866–879. https://doi.org/10.1038/s41386-021-01251-8
Lyall, L.M., Wyse, C.A., Graham, N., Ferguson, A., Lyall, D.M., Cullen, B., Celis Morales,
C.A., Biello, S.M., Mackay, D., Ward, J., Strawbridge, R.J., Gill, J.M.R., Bailey, M.E.S.,
Pell, J.P., Smith, D.J., 2018. Association of disrupted circadian rhythmicity with mood
disorders, subjective wellbeing, and cognitive function: a cross-sectional study of
91 105 participants from the UK Biobank. Lancet Psychiatry 5, 507–514.
https://doi.org/10.1016/S2215-0366(18)30139-1
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I.D., Salvadore,
G., Zarate, C.A., 2010. The Timing of Antidepressant Effects: A Comparison of Diverse
Pharmacological and Somatic Treatments. Pharmaceuticals 3, 19.
https://doi.org/10.3390/PH3010019
Madigan, D., Raftery, A.E., 1994. Model Selection and Accounting for Model Uncertainty in
Graphical Models Using Occam's Window. J Am Stat Assoc 89, 1535–1546.
https://doi.org/10.1080/01621459.1994.10476894
Morres, I.D., Hatzigeorgiadis, A., Krommidas, C., Comoutos, N., Sideri, E., Ploumpidis, D.,
Economou, M., Papaioannou, A., Theodorakis, Y., 2019a. Objectively measured
physical activity and depressive symptoms in adult outpatients diagnosed with major
depression. Clinical perspectives. Psychiatry Res 280, 112489.
https://doi.org/10.1016/j.psychres.2019.112489
Morres, I.D., Hatzigeorgiadis, A., Stathi, A., Comoutos, N., Arpin-Cribbie, C., Krommidas,
C., Theodorakis, Y., 2019b. Aerobic exercise for adult patients with major depressive
disorder in mental health services: A systematic review and meta-analysis. Depress
Anxiety 36, 39–53. https://doi.org/10.1002/da.22842
Østergaard, S.D., Jensen, S.O.W., Bech, P., 2011. The heterogeneity of the depressive
syndrome: when numbers get serious. Acta Psychiatr Scand 124, 495–496.
https://doi.org/10.1111/j.1600-0447.2011.01744.x
Pan, W., Song, Y., Kwak, S., Yoshida, S., Yamamoto, Y., 2014. Quantitative evaluation of
the use of actigraphy for neurological and psychiatric disorders. Behavioural Neurology
2014. https://doi.org/10.1155/2014/897282
Rabinowitz, J., Rabinowitz, A.A., 2022. Outlier-response pattern checks to improve
measurement with the Montgomery-Asberg depression rating scale (MADRS). J Affect
Disord 299, 444–448. https://doi.org/10.1016/j.jad.2021.12.076
Rabinowitz, J., Schooler, N.R., Brown, B., Dalsgaard, M., Engelhardt, N., Friedberger, G.,
Kinon, B.J., Lee, D., Ockun, F., Mahableshwarkar, A., Tsai, J., Williams, J.B.W.,

Sauder, C., Yavorsky, C., 2019. Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS). J Affect Disord 256, 143–147. https://doi.org/10.1016/j.jad.2019.05.077

Raftery, A.E., Madigan, D., Hoeting, J.A., 1997. Bayesian Model Aeraging for Linear Regression Models. J Am Stat Assoc 92, 179–191.

Saragiotis, C., 2021. Lomb normalized periodogram.

Sato, S., Bunney, B., Mendoza-Viveros, L., Bunney, W., Borrelli, E., Sassone-Corsi, P., Orozco-Solis, R., 2022. Rapid-acting antidepressants and the circadian clock. Neuropsychopharmacology 47, 805–816. https://doi.org/10.1038/s41386-021-01241-w

Silva, S., Bicker, J., Falcão, A., Fortuna, A., 2021. Antidepressants and circadian rhythm: Exploring their bidirectional interaction for the treatment of depression. Pharmaceutics 13. https://doi.org/10.3390/PHARMACEUTICS13111975

Simmonds-Buckley, M., Catarino, A., Delgadillo, J., 2021. Depression subtypes and their response to cognitive behavioral therapy: A latent transition analysis. Depress Anxiety 38, 907–916. https://doi.org/10.1002/da.23161

Sokolove, P.G., Bushell, W.N., 1978. The chi square periodogram: its utility for analysis of circadian rhythms. J Theor Biol 72, 131–160.

Spulber, S., Ceccatelli, S., Forsell, Y., 2025. Individual patterns of activity predict the response to physical exercise as an intervention in mild to moderate depression. J Affect Disord. https://doi.org/10.1016/j.jad.2025.01.097

Spulber, S., Elberling, F., Svensson, J., Tiger, M., Ceccatelli, S., Lundberg, J., 2022. Patterns of activity correlate with symptom severity in major depressive disorder patients. Transl Psychiatry 12, 226. https://doi.org/10.1038/s41398-022-01989-9

Svensson, J.E., Svanborg, C., Plavén-Sigray, P., Kaldo, V., Halldin, C., Schain, M., Lundberg, J., 2021. Serotonin transporter availability increases in patients recovering from a depressive episode. Transl Psychiatry 11, 264. https://doi.org/10.1038/s41398-021-01376-w

Tackenberg, M.C., Hughey, J.J., 2021. The risks of using the chi-square periodogram to estimate the period of biological rhythms. PLoS Comput Biol 17, 1–16. https://doi.org/10.1371/JOURNAL.PCBI.1008567

Taliaz, D., Spinrad, A., Barzilay, R., Barnett-Itzhaki, Z., Averbuch, D., Teltsh, O., Schurr, R., Darki-Morag, S., Lerer, B., 2021. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Transl Psychiatry 11. https://doi.org/10.1038/s41398-021-01488-3

Tazawa, Y., Wada, M., Mitsukura, Y., Takamiya, A., Kitazawa, M., Yoshimura, M., Mimura, M., Kishimoto, T., 2019. Actigraphy for evaluation of mood disorders: A systematic review and meta-analysis. J Affect Disord. https://doi.org/10.1016/j.jad.2019.04.087

Tiger, M., Veldman, E.R., Ekman, C.J., Halldin, C., Svenningsson, P., Lundberg, J., 2020. A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Transl Psychiatry 10, 159. https://doi.org/10.1038/s41398-020-0844-4

Weitz, E.S., Hollon, S.D., Twisk, J., van Straten, A., H Huibers, M.J., David, D., DeRubeis, R.J., Dimidjian, S., Dunlop, B.W., Cristea, I.A., Faramarzi, M., Hegerl, U., Jarrett, R.B., Kheirkhah, F., Kennedy, S.H., Mergl, R., Miranda, J., Mohr, D.C., John Rush, A., Segal, Z. V, Siddique, J., Simons, A.D., Vittengl, J.R., Cuijpers, P., Author, C., 2015. Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy An Individual Patient Data Meta-analysis Supplemental content at jamapsychiatry.com Original Investigation | META-ANALYSIS. JAMA Psychiatry 72, 1102–1109. https://doi.org/10.1001/jamapsychiatry.2015.1516

734   **Table 1.** Description of patient cohorts and antidepressant treatments

Treatment	pre	post	both[1]	Treatment scheme	Ref
HC	19[2] (14)	N/A	N/A	N/A	(Svensson et al., 2021)
iCBT	12 (9)	11 (9)	8 (6)	10 self-administered, internet-delivered sessions (1 session/week)	(Svensson et al., 2021)
Escitalopram	7 (3)	6 (2)	5 (2)	10 mg/ day	(Gärde et al., 2024)
Ketamine	16 (8)	15 (6)	12 (6)	0.5 mg/kg i.v. infusion, 2/week	(Tiger et al., 2020)

Numbers in parentheses indicate the number of female subjects in each group.

[1] – used for paired comparisons, post vs. pre

[2] – 1 subject was recorded 3 times; 1 subject was recorded 2 times; 16 independent subjects

Fig. 1 Description of source data. (**A**) Timeline for data collection for all cohorts included.

Only subjects for which actigraphy recordings were available are shown. (**B**) Change in

MADRS score in individual subjects for each cohort. (**C**) Distribution of MADRS scores

before and after treatment in pooled cohorts. The subjects with MADRSpost < 10 are

included in the "remission" group in subsequent analyses.

Fig. 2 Changes in patterns of activity associated with ongoing antidepressive treatment.
(**A**) Between-group differences in individual features. Each treatment group is compared against MDD subjects before treatment as reference. MDD subjects before treatment are compared against healthy controls. The heatmap in the left panel displays the ratios between each group average and their respective reference group average. Significant differences surviving FDR correction are displayed in the right panel. Note the distinct signatures of individual treatments. Subjects in remission (independent of antidepressant treatment) display no significant differences from MDD subjects before treatment (remission) or from healthy controls (remission*). (**B**) Correlations between changes in individual features and the magnitude of response to treatment. Daily variability of IS (vIS30) and timing of circadian peak (M10L) appear to correlate with the response to treatment independently from actual antidepressive treatment.

Fig. 3 Correlations between activity features before treatment and the response to

different antidepressant treatments. (**A**) Correlations with magnitude of response to

treatment. Left panel: heatmap of raw correlation coefficients. Right panel: correlation

coefficients surviving FDR correction. Note that response to treatment regardless of the nature

of antidepressant treatment does not correlate with any individual feature, and that individual

treatments have distinct signatures in terms of individual features correlating with the

magnitude of the response. (**B**) Parallel training of ensembles of multiple regression models

for response to treatment. Illustration of evaluation of performance for individual models. (**C**)

Evaluation of performance of pruned ensembles. Aggregated output is calculated as

cumulative average of individual model output, after sorting the ensembles by decreasing

accuracy (increasing RMSE).

Fig. 4 Bayesian analysis of coefficients. (**A**) Analysis of occurrence and variability of individual features in each ensemble. Features mapping above the threshold for PIP (set to prior inclusion probability, 0.2035) are defined as "enriched" since after pruning they are encountered more often than estimated. Features mapping in the top-left region have stable

coefficients and have medium to strong evidence of correlation with the magnitude of
response to treatment. (**B**) Average standardized coefficients for all ensembles to illustrate the
differences in ensemble composition. The heatmap in the first panel shows all average
standardized coefficients. The second and third panel display only the coefficients with PIP >
0.2035 (above threshold in (A)). Note the distinct, non-overlapping signatures for each
ensemble. (**C**) Direct comparison between effect sizes of individual features in ensembles
modeling the response to iCBT and ketamine. Enriched features highlighted and color-coded
based on differential enrichment in either ensemble. Features mapping in top-right and
bottom-left quadrants indicate similar effects, while features mapping in top-left and bottom-
right quadrants indicate opposite effects between ensembles.